The strategic acquisitions expand the company’s structural heart disease technologies.
The deal will help J&J speed up its entry into the robotics market.
The deal will help strengthen the Edwards portfolio of smart monitoring technologies.
The $701-million deal is expected to enhance Stryker’s cross-specialty surgical visualization for surgeons.
The union will strengthen BD’s leadership in medication management and infection prevention, and increase opportunities in fast-growing clinical areas and OUS markets.
Medtronic will keep its respiratory and monitoring solutions business, while Cardinal will buy the patient care, DVT, and nutritional insufficiency businesses.
The $435-million deal is part of the company’s commitment to being a leader in products for transcatheter aortic valve implantation.
The deal is pending acceptance by Johnson & Johnson.
The acquisition adds to the company’s plastic surgery and regenerative medicine portfolio.
You can never do enough due diligence.